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University, Wales, UKA B S T R A C TBackground: At present, there is no universal deﬁnition of rare
disease. Objective: To provide an overview of rare disease deﬁnitions
currently used globally. Methods: We systematically searched for
deﬁnitions related to rare disease from organizations in 32 interna-
tional jurisdictions. Descriptive statistics of deﬁnitions were gener-
ated and prevalence thresholds were calculated. Results: We
identiﬁed 296 deﬁnitions from 1109 organizations. The terms “rare
disease(s)” and “orphan drug(s)” were used most frequently (38% and
27% of the deﬁnitions, respectively). Qualitative descriptors such as
“life-threatening” were used infrequently. A prevalence threshold was
speciﬁed in at least one deﬁnition in 88% of the jurisdictions. The
average prevalence threshold across organizations within individual
jurisdictions ranged from 5 to 76 cases/100,000 people. Most juris-
dictions (66%) had an average prevalence threshold between 40 and
50 cases/100,000 people, with a global average of 40 cases/100,000
people. Prevalence thresholds used by different organizations withinee front matter Copyright & 2015, International S
r Inc.
.1016/j.jval.2015.05.008
cadth.ca.
ndence to: Trevor Richter, CADTH, 600-865 Carlingindividual jurisdictions varied substantially. Across jurisdictions,
umbrella patient organizations had the highest (most liberal) average
prevalence threshold (47 cases/100,000 people), whereas private payers
had the lowest threshold (18 cases/100,000 people). Conclusions:
Despite variation in the terminology and prevalence thresholds used
to deﬁne rare diseases among different jurisdictions and organizations,
the terms “rare disease” and “orphan drug” are used most widely and
the average prevalence threshold is between 40 and 50 cases/100,000
people. These ﬁndings highlight the existing diversity among deﬁni-
tions of rare diseases, but suggest that any attempts to harmonize rare
disease deﬁnitions should focus on standardizing objective criteria such
as prevalence thresholds and avoid qualitative descriptors.
Keywords: orphan drugs, prevalence, rare disease, terminology.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Background to the Rare Disease Working Group
In June 2013, the Rare Disease Terminology & Deﬁnitions Used in
Outcomes Research Working Group was established under the
auspices of the ISPOR Rare Disease Special Interest Group.
Members developed the concept because of the lack of a univer-
sal deﬁnition of rare diseases or the technologies used in their
treatments and the existing diversity in the use of different
deﬁnitions used to describe rare diseases and the underlying
connotations associated with them.
The leadership group represents a diverse range of perspec-
tives. They work in regulatory agencies, research organizations,
academia, and the pharmaceutical industry. In addition, the
group was international, comprising ISPOR members from the
United Kingdom, Germany, Serbia, Belgium, Canada, Italy, TheNetherlands, Switzerland, and the United States. In addition,
local researchers in Latin America and Asia Paciﬁc contributed to
the ﬁndings in those parts of the world.
The leadership group met approximately every 5 weeks by
teleconference to develop an outline and methodology, enlist
volunteer researchers through ISPOR’s regional chapters as well
as discuss the literature review, ﬁndings, analysis, translations,
and issues that arose during the course of manuscript develop-
ment. In addition, members met in person at the ISPOR Annual
European congresses in Dublin and Amsterdam and the ISPOR
International Meeting in Montreal.
Preliminary ﬁndings were presented in a forum presentation
at the 2013 ISPOR Annual Meeting in Dublin, and a ﬁrst draft was
presented at the ISPOR Annual International Meeting in Montreal.
Oral comments were received during the presentations. Writtenociety for Pharmacoeconomics and Outcomes Research (ISPOR).
Avenue, Ottawa, ON, Canada K1S 5S8.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 9 0 6 – 9 1 4 907comments were received during two rounds of review with the
200þ person ISPOR Rare Disease Review Group.
All comments were considered, and most were substantive
and constructive. Comments were addressed as appropriate in
subsequent versions of the report.Table 1 – Search terms used to identify deﬁnitions.
Highly specialized technology
Neglected disease
Orphan disease
Orphan drug
Orphan medicinal product
Orphan product
Orphan subset
Rare and neglected disease
Rare condition
Rare disease
Rare disorder
Syndrome without a name
Ultraorphan disease
Ultraorphan drug
Ultrarare disease
Undiagnosed disease
Very rare diseaseIntroduction
Increased focus on rare diseases over the last several decades has
been spurred mainly by legislation intended to facilitate patient
access to effective treatments by incentivizing pharmaceutical and
biotechnology companies to develop new medicines that would
otherwise not be proﬁtable [1]. As an indication of the success of the
1983 Orphan Drug Act in the United States, more than 420 orphan
drugs and biologic products for rare diseases have been approved by
the Food and Drug Administration (FDA), compared with fewer than
10 such products in the decade before the Act [2,3]. Similarly, since
2000, when the European Union (EU) established procedures for
orphan drug application and incentives for development in their EU
Regulation on Orphan Medicines (EC/141/2000) to address rare
conditions, 84 orphan drugs have received market authorization
by the EU Commission, 2 of which were subsequently withdrawn
[4]. Increased attention on rare diseases has also resulted from an
improved genetic, molecular, and biochemical understanding
resulting from recent scientiﬁc and technological advances [5].
A rare disease is a health condition that affects a small
number of people compared with other prevalent diseases in
the general population. To date, between 5000 and 8000 distinct
rare diseases have been documented [4], and new rare diseases
are reported regularly in the medical literature [5,6]. Social
awareness uptake and global connectedness in the area of rare
diseases is noticeable. For example, when the ﬁrst Rare Disease
Day began in 2008, only 18 jurisdictions participated compared
with 84 in 2014 [4]. The total number of patients affected is large
(e.g., 27–36 million people in the EU and 25 million in the United
States [5]), posing important challenges to health care providers,
particularly in the context of escalating costs [6,7].
It is important that the terminology related to deﬁnitions of
rare diseases is understood by different stakeholder groups.
Understanding is complicated by the deﬁnitions themselves,
which differ according to the context in which they are used
(such as rare disease advocacy groups vs. private payers) and
applied (e.g., for regulatory approval vs. reimbursement).
Most deﬁnitions appear to at least consider disease preva-
lence, but other criteria sometimes also apply, including disease
severity, whether the disease is life-threatening, whether there
are alternative treatment options available, and whether it is
heritable [8,9]. The use of diverse terminology and the use of
inconsistent deﬁnitions can result in confusion and inconsisten-
cies in access to treatment. The absence of agreed deﬁnitions for
rare disease terminology has also aided the increased colloquial
use of some terms for rare diseases, such as “ultraorphan” or
“neglected,” in a way that might not always correspond to the
formal deﬁnitions of these terms. In addition, some terms may be
implicitly associated with emotional connotations (e.g., “life-
threatening,” “orphan,” and “neglected”) that may differ depend-
ing on the type of organization making reference to the term.
Despite progress in a wide range of collaborative regulatory
and patient-related activities internationally, there is no global
consensus deﬁnition of rare disease and related health care
interventions. Moreover, the extent of global variation in deﬁni-
tions related to rare disease is unclear.
This article presents a review of the terminology used in
deﬁnitions for rare disease and associated health technologies
identiﬁed from a systematic Web search of documenta-
tion from 32 relevant national and international organizationsfrom six geographic regions. Our review provides a comprehensive
overview of the commonalities and differences that exist in
deﬁnitions used across the relevant types of organization and
multiple jurisdictions globally.Methods
Search Process
Members of the International Society for Pharmacoeconomic and
Outcomes Research (ISPOR) who volunteered to participate
actively in this research were invited to join the leadership group.
They represented a diverse range of stakeholders, including
regulatory, academic, pharmaceutical industry, and patient organ-
izations. Reﬂecting ISPOR membership demographic character-
istics, they were predominantly from Europe and North America.
The systematic search process was developed in three steps.
First, the leadership group identiﬁed English-language terms
used in the context of deﬁning rare disease and associated health
technologies (Table 1). The search terms were created with the
aim of capturing all relevant deﬁnitions to generate a compre-
hensive audit of deﬁnitions currently in use, and were not
restricted or categorized to reﬂect potential subcategories of
deﬁnitions, such as “very rare” or “ultrarare” disease.
Second, the leadership group identiﬁed the types of agencies
and organizations that were likely relevant, and classiﬁed them as
health technology assessment (HTA) agency, private payer, public
payer, regulator, research center, umbrella patient organization, or
other (including pharmaceutical trade organizations and nonregu-
latory government agencies), as presented in Table 2. To make the
review more manageable, we included only those patient organ-
izations that were not disease-speciﬁc, that is, umbrella patient
organizations and advocacy groups (Table 2). Umbrella organiza-
tions were included if they were jurisdiction-speciﬁc. Variations in
the mix of national organizations included in the analysis were
permitted across jurisdictions, expecting that some jurisdictions
would not have all the agencies or organizations speciﬁed.
The leadership group ﬁnally selected jurisdictions that repre-
sented each of the six geographic regions of the world (North
America, South America, Asia, Europe, Africa, and Oceania).
These are listed in Table 3. Jurisdictions were included only if
there was a positive response to the solicitation to participate
and if there was information publicly available. For example,
Liberia could not be included because there was no relevant
information available on any Web sites that were searched.
Table 2 – Organization types included in the search.
Organization Deﬁnition Example
Health
technology
assessment
agency
Agencies with a
primary mandate
to carry out health
technology
assessments,
including
governmental,
quasi-
governmental,
and
nongovernmental
organizations
National Institute for
Health and Care
Excellence (NICE)
in the United
Kingdom
Private payer Organizations such
as private health
insurance
providers
Aetna in the United
States
Public payer Public health
insurance
providers
Ontario Drug Beneﬁt
Program in
Canada
Regulator Regional and
national
government
agencies that
regulate
pharmaceuticals
and medical
devices
Food and Drug
Administration
(FDA) in the
United States
Research
center
Includes any
research-focused
organizations, not
restricted to those
with a special
interest in rare
diseases
National Center for
Advancing
Translational
Sciences in the
United States
Umbrella
patient
organization
Includes advocacy
(patient) groups,
policy groups, and
organizations that
provide resources
for patients with
rare diseases
National
Organization for
Rare Disorders
(NORD)
Other Any organization
that could not be
classiﬁed into one
category was
categorized as
“Other,” including
pharmaceutical
trade
organizations and
nonregulatory
government
agencies
The Ignite Project in
Canada
Table 3 – List of jurisdictions included in the search.
Region Jurisdiction Data veriﬁed
Africa South Africa
Asia China x
India x
Japan x
Korea
Russia
Taiwan
Turkey x
Europe Czech Republic x
Denmark x
England x
European Union x
France
Germany
Ireland
Italy x
The Netherlands x
Poland x
Scotland x
Slovakia x
Spain
Sweden x
United Kingdom x
Wales x
North America Canada x
Mexico
United States
Oceania Australia x
South America Argentina
Brazil x
Chile x
Colombia
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who spoke the native language for the jurisdiction in which they
were asked to search for information according to the methods
described below.
Data Collection
Data collection comprised a systematic Internet-based search
that was carried out between December 2, 2013, and April 17,2014. Each member of the working group searched for each of the
17 terms in Web sites relevant to each organization and any
documentation contained therein. The researchers had discre-
tion in determining equivalent terms in other languages, recog-
nizing that terms might not translate directly. Researchers
applied their local knowledge to identify relevant agencies and
organizations.
If a term was found in documentation available for a given
organization, the full deﬁnition that included the search term (in
the native language), as well as the source (a complete list of the
sources of deﬁnitions identiﬁed is available from the correspond-
ing author on request) (valid reference hyperlink), was recorded
on a jurisdiction-speciﬁc data extraction table. A standardized
template for data recording was used for all local searches to
ensure consistency of search terms and data format. Deﬁnitions
in a language other than English were transcribed and recorded
in both the original language and English. If more than one
deﬁnition was found on the same Web site, both deﬁnitions were
recorded. If a term was not found, a null ﬁnding was recorded in
the database. If another term was found that was not among the
predeﬁned search terms, it was added to the spreadsheet with
the requisite deﬁnition and source information.
A central data management process, overseen by the ISPOR
Rare Disease Special Interest Group liaison, ensured that the
database was veriﬁed as having been completed appropriately,
and data recorded correctly. Speciﬁcally, a single individual
collected and collated all local search results into a single
electronic master database. Collation and data entry were then
Table 4 – Frequency of terms used across all 296
deﬁnitions identiﬁed.
Search term Number of
deﬁnitions
Proportion
of total (%)
Rare disease* 112 38
Orphan drug 79 27
Orphan disease 18 6
Orphan medicinal product 16 5
Rare disorder 11 4
Ultrarare disease 10 3
Highly specialized
technologies
9 3
Rare condition 9 3
Neglected disease 5 2
Ultraorphan drug 4 1
Orphan product 4 1
Very rare disease 4 1
Orphan indication† 2 1
Low-frequency disease† 2 1
Pharmacological therapies
of high complexity†
2 1
Rare disability† 2 1
Ultraorphan disease 2 1
Priority review drugs† 1 o1
Orphan pharmaceutical
product†
1 o1
Syndrome without a name 1 o1
Rare and neglected disease 1 o1
Extremely rare disease† 1 o1
Orphan subset† 1 o1
Rare medicinal technology† 1 o1
* Includes deﬁnitions that use qualiﬁers in addition to “rare
disease” such as “intractable,” for example, in deﬁnitions used
in Japan and Korea.
† Terms included by local researchers for use during searches but
not included in the original list of search terms.
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that were incomplete or improperly recorded were returned to
the researcher with directions on how to satisfy the requirements
for adequate reporting.
If a researcher was unable to complete the task as per
protocol, or if local language ﬂuency was an issue, a volunteer
researcher located in the target jurisdiction was identiﬁed to
assist in the completion and veriﬁcation of the task/content.
These in-country researchers were identiﬁed through the ISPOR
regional chapters, the ISPOR Regional Consortia, or the ISPOR
member database. In most cases, the original spreadsheet was
sent to the veriﬁer to check the original researcher’s ﬁndings. If
any of the original researcher’s ﬁndings were deemed incorrect or
missing, the veriﬁer added that information through another
search.
Data Analysis
Data from each jurisdiction, including the United Kingdom and
the EU, were combined into a master database for analysis. We
calculated the frequency with which each search term (e.g., “rare
disease”) and individual descriptors (e.g., “rare”) were used within
the deﬁnitions that were identiﬁed. Identiﬁed deﬁnitions were
reviewed to determine how frequently the following qualitative
descriptors were used: “life-threatening” (or “life threatening”),
“debilitating,” “not available,” “unavailable,” “not possible,” “sev-
ere,” “intractable,” “no treatment,” “no alternative,” “no cure,”
“incurable,” “fatal.” We also calculated the frequency with which
the terms “genetic,” “hereditary,” or “heritable” were used. We
also examined the distribution of deﬁnitions per jurisdiction and
organization type.
Prevalence thresholds used in each deﬁnition were converted
to absolute frequency and number of cases per 100,000 people
[10,11]; an average value was used if a range of thresholds was
presented within a single deﬁnition. Where prevalence was not
speciﬁed but was implied in the deﬁnition, for example, if there
was a speciﬁcation of the patient population size, we calculated
the implied prevalence using the size of the population (as of
2014) in the jurisdiction of interest. Prevalence thresholds used in
deﬁnitions were examined for individual jurisdictions, geo-
graphic regions, and organization type.
Jurisdiction-speciﬁc thresholds were estimated by calculating
the average value from all organizations within that jurisdiction.
We calculated the coefﬁcient of variation, deﬁned as the ratio of
the SD to the mean of the distribution of prevalence thresholds
for individual jurisdictions.Results
Terminology Used in Deﬁnitions
A total of 1109 agencies or organizations were searched from 32
jurisdictions, resulting in the identiﬁcation of 296 deﬁnitions. In
addition to the 17 search terms, researchers identiﬁed 6 addi-
tional terms that were used as search terms (see Table 4). Only
those terms that were used in at least one deﬁnition (N ¼ 23; see
Table 4) were included in the analysis.
With 112 deﬁnitions, the most frequently deﬁned term was
“rare disease(s).” This term accounted for 38% of all deﬁnitions
and was deﬁned more frequently than “orphan disease(s)” (18
deﬁnitions; 6%) (Table 4). Seventy-nine deﬁnitions of “orphan
drug(s)” were identiﬁed.
Among the descriptors used to refer to a type (i.e., adjectives),
“rare” was used most frequently (used in 151 deﬁnitions),
although “orphan” was also used frequently (127 deﬁnitions).
Both these terms were used much more often than other relateddescriptors such as “neglected” (6 deﬁnitions) and “specialized” (9
deﬁnitions) (Table 5). Among adjectives used as descriptors in
deﬁnitions, “rare” was the most frequent (52% of the deﬁnitions).
Among the descriptors used to refer to rarity (modiﬁers),
“ultra” (used in 16 deﬁnitions) was used more frequently than
“very” (4 deﬁnitions), although both descriptors were seldom
used (Table 5).
Among the descriptors used to refer to a condition (i.e.,
nouns), “disease” (used in 153 deﬁnitions) was used most fre-
quently and was used more often than “condition” (9 deﬁnitions),
“disability” (2 deﬁnitions), and “syndrome” (1 deﬁnition) (Table 5).
Few deﬁnitions used qualitative descriptors of the severity of
the disease; indeed, most deﬁnitions (N ¼ 208; 70%) did not use
such terms. When a descriptor(s) was used, the most prevalent
was the use of two terms (19%) followed by 9% with one
descriptor. No deﬁnitions used more than three such terms.
The qualitative descriptors that were used most frequently were
“life-threatening” (15%), followed by “debilitating” (10%), “severe”
(3%), and “intractable” (1%). Terms related to genetics were used
very infrequently in deﬁnitions: only 10 (3.4%) deﬁnitions used
the term “genetic,” whereas only 1 deﬁnition used the term
“hereditary” and no deﬁnitions used the term “heritable.”
When the number of deﬁnitions identiﬁed was stratiﬁed
according to the type of organization, the umbrella patient
organizations and research centers had a relatively higher pro-
portion of deﬁnitions of rare disease than did other types of
organizations (Table 6). We identiﬁed at least one deﬁnition in
Table 5 – Frequency of use of individual descriptors*
of interest in deﬁnitions.
Term N Proportion (%)
Type descriptor (adjective)
Rare 151 51.6
Orphan 127 43.5
Specialized 9 3.2
Neglected 6 1.6
Rarity descriptor (modiﬁer)
Ultra 16 75.0
Very 4 25.0
Condition descriptor (noun)
Disease 153 92.7
Condition 9 5.5
Disability 2 1.2
Syndrome 1 0.6
* Descriptors have been grouped as adjectives, verbs (modiﬁers),
and nouns.
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tions that were searched (Table 6). In contrast, deﬁnitions were
identiﬁed in only 27% of regulatory agencies, 25% of HTA
agencies, 17% of public payers, and 8% of private payers (Table 6).
Prevalence Thresholds
Most deﬁnitions explicitly or implicitly included a prevalence
threshold (172 of 296 deﬁnitions [58%] deﬁnitions). When strati-
ﬁed by geography, 28 of 32 (88%) jurisdictions included a preva-
lence threshold in at least one deﬁnition of rare disease. Scotland,
Mexico, Wales, and Turkey speciﬁed prevalence in all (100%)
deﬁnitions for rare disease we identiﬁed in these countries. Only
the United States, Australia, and Japan did not specify prevalence
explicitly in any deﬁnition. We identiﬁed only one instance in
which incidence was speciﬁed in a deﬁnition of rare disease (an
umbrella patient organization in China). Therefore, it appears
that prevalence is the universally preferred epidemiology metric
used in deﬁnitions of rare disease.
Where prevalence was speciﬁed explicitly, various forms of
expression were used, including being expressed as a fraction (e.
g., 0.00040), as a percentage, or as the number of cases/10,000 or
100,000 people. Prevalence thresholds ranged from 1 case/
1,000,000 people, which was used to deﬁne ultrarare disease by
an HTA agency in Italy (Unità di Valutazione dell’Efﬁcacia delTable 6 – Number of organizations for which deﬁnitions
Organization type Number of deﬁnitions
identiﬁed (A)
Private payer 10
Public payer 48
Health technology assessment
agency
40
Regulator 78
Umbrella patient organization 89
Other* 22
Research center 9
Total 296
* Includes any organization that could not be classiﬁed into a category
government agencies.Farmaco: www.uvef.it), to 150 cases per 100,000 people, which
was used in a deﬁnition by an umbrella patient organization in
China (CHINA-DOLLS Center for Rare Disorders: http://chinadolls.
org.cn/page/4365).
The geographic distribution of prevalence thresholds for
individual jurisdictions (averaged across all deﬁnitions for each
jurisdiction) is presented in Figure 1, and the corresponding
average prevalence values are presented in Table 7. The average
prevalence thresholds ranged from 5 cases/100,000 for Korea to
76 cases/100,000 people for China.
Note that the range for the average prevalence is presented to
illustrate that different prevalence thresholds are used within
individual jurisdictions across all deﬁnitions identiﬁed. For exam-
ple, the average value of 40 cases/100,000 people for the EU
includes deﬁnitions from nonregulatory organizations, which
specify lower prevalence thresholds than the 50 cases/100,000
used in the European Medicines Agency deﬁnition. When aver-
aged across jurisdictions, the global average prevalence was 40
cases/100,000 people, which was equal to the global median
prevalence of 40 cases/100,000 people. More than half the juris-
dictions in our sample (21 of 32, or 66%) had an average
prevalence threshold that was between 40 and 50 cases/100,000
people. The coefﬁcient of variation for the average prevalence
thresholds for individual jurisdictions was 0.44.
Examination of the distribution of prevalence per organization
type (Table 8), irrespective of geographic location, revealed that
umbrella patient organizations had the highest average preva-
lence threshold among organization types (46 cases/100,000
people; range o1–150), whereas private payers had the lowest
values (28 cases/100,000 people; range 1–64). Regulators, HTA
agencies, and public payers were intermediate (30–41 cases/
100,000 people; range o1–65).
When the range in prevalence thresholds for deﬁnitions used
by different types of organization was examined within individual
jurisdictions, there was substantial variability (data not shown).Discussion
We identiﬁed deﬁnitions pertaining to rare diseases and associ-
ated concepts and health technologies in all jurisdictions
searched, and deﬁnitions were identiﬁed in a diverse range of
organizations within individual jurisdictions. The broad repre-
sentation of jurisdictions and organizations that we found to
have deﬁned rare disease and/or associated technologies sug-
gests that there is a universal desire to distinguish “rare diseases”
from “common diseases” in a formal manner. This reﬂects a
growing international trend to establish speciﬁc health policieswere identiﬁed.
Number of organizations
searched (B)
Proportion of
total
(A/B) (%)
125 8
290 17
158 25
289 27
186 48
44 50
17 53
1109
, including pharmaceutical trade organizations and nonregulatory
Fig. 1 – Regional distribution of prevalence thresholds for jurisdictions included in the present study. The size of the circles
corresponds to the average prevalence threshold (number of cases per 100,000 people) for all organizations within a
jurisdiction. Black and white circles correspond to jurisdictions in which the average prevalence in deﬁnitions of rare disease
is lower or higher, respectively, than the average across all jurisdictions in this study of 40 cases/100,000 people.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 9 0 6 – 9 1 4 911for rare diseases. It is important to note that our study has
focused on the terminology used to deﬁne rare disease; clariﬁca-
tion of the concept of what constitutes a rare disease represents
an important area for further research.
Our ﬁnding that more than six times as many deﬁnitions used
the term “rare disease” rather than “orphan disease” suggests
that “rare disease” is the preferred terminology. The observation
that the term “orphan drug” was used in many deﬁnitions
suggests that “orphan” is predominantly used in the context of
deﬁning the technologies associated with the treatment of rare
diseases. Most deﬁnitions that we identiﬁed were relatively
rigorous and were based on objective, or measurable, criteria.
Although few deﬁnitions used terminology that was qualitative
and less objective, such as “life-threatening,” including terms
that could be emotionally loaded, such as “debilitating,” a
prevalence threshold was used either explicitly or implicitly in
most (58%) of the deﬁnitions that we identiﬁed. In addition, we
found that at least one deﬁnition of rare disease in every
jurisdiction searched included a prevalence threshold. These
ﬁndings suggest that disease prevalence is the preferred epi-
demiology metric used in deﬁnitions of rare disease. Indeed,
prevalence rather than incidence is the most appropriate metric
because this reﬂects how widespread a disease is (as opposed to
reﬂecting the rate of occurrence) and is amenable to use for
speciﬁc subpopulations. More importantly, the use of prevalence
facilitates international comparison.
A notable distinction between the deﬁnitions of rare disease
in the context of orphan medicinal products provided by the
main regulatory authorities in the United States, the EU, and
Japan (Table 9) is the absence of an explicit prevalence threshold
in the US and Japanese deﬁnitions of a rare disease [3,12–14].
Although prevalence is not speciﬁed explicitly in the FDAdeﬁnition, a disease prevalence of 64 cases/100,000 people is
implied [3], based on current estimates of the size of the
population of the United States (as of 2014).
The global average prevalence threshold across all organiza-
tions within the jurisdictions in which we identiﬁed deﬁnitions
was 40 cases/100,000 people. There is variability among individ-
ual jurisdictions with regard to the prevalence threshold cited in
publicly available deﬁnitions of rare disease [1,15,16]. Our results
indicate that the average prevalence thresholds used in different
jurisdictions range from 5 to 76 cases/100,000 people, with even
more variability among different organizations within individual
jurisdictions. Although this represents a 15-fold relative differ-
ence in the average prevalence thresholds used to deﬁne rare
diseases in different jurisdictions, most jurisdictions (N ¼ 21 or
66%) had an average prevalence threshold of between 40 and 50
cases per 100,000 people, that is, an absolute difference of 15
cases/100,000 people.
Despite (or perhaps because of) such variation, recent
developments in the EU are moving toward a harmonized
deﬁnition of rare disease, at least in the political arena.
Speciﬁcally, the European Council Recommendation on an
action in the ﬁeld of rare diseases required all EU member
states to recommended adoption of national plans and policies
for rare disease by the end of 2013, and the “adequate deﬁni-
tion” of rare diseases is endorsed speciﬁcally [12]. Most EU
member states have since published their national rare disease
plans, and it is noteworthy that most governments have
adopted the EU deﬁnition of a rare disease (affecting no more
than 5/10,000 persons) as a deﬁnition of rare disease in their
national strategies [17], suggesting a marked shift in Europe
toward harmonization of a prevalence threshold for the rare
disease on a political level.
Table 7 – Average prevalence used in deﬁnitions per jurisdiction.
Jurisdiction Cases per 100,000 people Range
Min. Max.
Korea 5 5 5
Australia 9 9 9
Taiwan 10 10 10
Denmark 13 1 20
Russia 19 7 50
Sweden 21 10 50
South Africa 25 25 25
Turkey 38 1 50
Canada 38 1 50
Wales 38 2 50
The Netherlands 39 1 50
Japan 39 39 39
European Union 40 2 50
United Kingdom 40 1 50
England 40 1 50
Scotland 40 2 50
Spain 43 2 50
Italy 43 o1 50
Poland 45 2 60
Germany 46 12 50
Czech Republic 50 50 50
Argentina 50 50 50
Colombia 50 50 50
Mexico 50 50 50
Slovakia 50 50 50
France 50 50 50
Chile 50 50 50
Ireland 50 50 50
India 51 2 100
Brazil 58 50 65
United States 64 64 64
China 76 o1 150
Global average 40
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 9 0 6 – 9 1 4912If these developments in Europe are indicative of a growing
appetite for international standardization of deﬁnitions for rare
disease, our ﬁndings suggest that one component of such a
harmonized deﬁnition could be the use of a prevalence threshold
of between 40 and 50 cases/100,000 people. In addition, our
ﬁndings suggest that using terminology such as “rare disease”
would be preferential in a universal deﬁnition of rare disease
because this would conform to the most widely used terminology
in current use. Terms such as “orphan drug” should be reserved
for use in deﬁnitions related to the technologies associated with
the treatment of rare diseases.Table 8 – Average prevalence thresholds used in deﬁniti
Organization type Cases per 1
Private payer
Health technology assessment agency
Public payer
Regulator
Other
Umbrella patient organizationSimilarly, very few deﬁnitions made reference to genetics, as
illustrated by our ﬁnding that the term “genetic” was used in only
10 deﬁnitions. This might reﬂect the fact that not all rare diseases
result from genetic defects and the causes of many rare diseases
remain unknown. It should be noted that although terms such as
“neglected disease” and “ultrarare disease” were included as
search terms, this does not imply that these terms describe
conditions that should be viewed as similar to rare diseases in
general. Indeed, we did not subgroup the search terms a priori to
differentiate between the high and low end of the prevalence
range, but our ﬁndings suggest that deﬁnitions used for “veryons per organization type.
00,000 people Range
Min. Max.
28 1 64
30 o1 60
31 o1 65
41 1 64
44 1 64
46 o1 150
Table 9 – Deﬁnitions of “rare disease” from promi-
nent regulatory agencies.
Jurisdiction Organization Deﬁnition of rare
disease
United
States
Food and Drug
Administration
The term “rare disease or
condition” means any
disease or condition
that (A) affects
o200,000 persons in
the United States,
or (B) affects >200,000
in the United States
and for which there is
no reasonable
expectation that the
cost of developing and
making available in
the United States a
drug for such disease
or condition will be
recovered from sales in
the United States of
such drug.
European
Union (EU)
European
Medicines
Agency
Rare diseases are deﬁned
as life-threatening or
chronically debilitating
conditions that affect
no more than 5 in
10,000 people in the
EU.
Japan* Ministry of
Health, Labour
and Welfare
(MHLW)
The number of patients
who may use the drug
or medical device
should be o50,000 in
Japan.
* Note that the data analysis was based on the Japanese MHLW
deﬁnition issued before the update released on May 23, 2014.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 9 0 6 – 9 1 4 913rare” and “ultrarare” diseases and conditions could be viewed as
a distinct subcategory within rare diseases. When deﬁnitions for
“very rare” and “ultrarare” disease were excluded from the
analysis of prevalence thresholds, the global average prevalence
threshold increased from 40 to 44 cases/100,000 people, reﬂecting
the lower prevalence thresholds used in such deﬁnitions.
Adopting a standardized prevalence threshold for deﬁning
rare disease internationally would be challenging, and might not
be desirable given region-speciﬁc demographic, political, and
ﬁnancial (and other) considerations. Indeed, we observed a wide
range in prevalence thresholds used by different types of organ-
ization within individual jurisdictions, which likely reﬂects the
differences in mandates and remits of the various organizations.
When it comes to deﬁning rare disease, the primary interests of
payers, which are heavily weighted to account for health care
utilization costs, may not be aligned with the primary goals of
patient groups, which are focused on access to effective treat-
ments, or those of policymakers, whose priority may lie primarily
in improving efﬁciency in the delivery of health care. Indeed, the
growing number of high-cost treatments for rare diseases is likely
to have an impact on pharmaceutical expenditure.
Because health care policy is usually controlled at national
and regional levels, differences in deﬁnitions (e.g., different
prevalence thresholds) across different organizations within a
jurisdiction could pose a much greater challenge for policy-
makers than differences across jurisdictions, particularly withrespect to the potential consequences of different national
prevalence thresholds to access and equality of access to health
care technologies for the treatment of rare diseases. This chal-
lenge is illustrated by our ﬁnding that not only have private and
public payers produced relatively few deﬁnitions compared with
other types of organization, but the deﬁnitions that have been
published by payer organizations tend also to be more stringent
than those published by other organizations.
Despite the aforementioned challenges, we suggest that future
development of deﬁnitions of rare disease should focus on objec-
tive, quantitative metrics such as prevalence and avoid the use of
qualitative descriptors. The use of nonobjective descriptors could
still be accommodated in conceptual deﬁnitions of rare disease,
whereas operational deﬁnitions require the rigor and objectivity
imparted by the use of speciﬁc prevalence thresholds.
Study Limitations
Our study has several limitations that should be highlighted.
First, not all data from all jurisdictions were veriﬁed independ-
ently. Therefore, data for unveriﬁed jurisdictions may be more
likely than data for veriﬁed jurisdictions to contain errors. We
note, however, that minimal changes were made to data as a
result of veriﬁcation, and in addition, the consolidated database
was quality checked independently.
Second, several geographic regions (notably Oceania and
Africa) had relatively few representative jurisdictions that were
included in the search. Therefore, there may be sampling bias in
terms of geographic representation and consequently a bias in
the deﬁnitions that were discovered. The representation of
regions and jurisdictions in our sample, however, is an accurate
reﬂection of the global distribution of resources applied to clinical
research, and includes all the major markets within which rare
diseases have emerged as an issue.
Third, it was sometimes difﬁcult to adequately translate
terminology from some non-English languages into English. The
result is that the frequency of terms used in deﬁnitions from non-
English sources may not precisely reﬂect the use of such termi-
nology in the local context. For example, in Italy, the terms “rare
disease,” “orphan disease,” and “rare condition” appear to be
used synonymously. It is not clear how this might have biased
the results, although we note that we accepted each translator at
face value to avoid introducing a bias into which terms were used
in the English translations.Conclusions
Our systematic review of deﬁnitions of rare disease revealed that
despite variation in the particular terminology and prevalence
thresholds used to deﬁne rare diseases among different jurisdictions
and types of organization, both within and among jurisdictions,
there is some global consistency in using the terms “rare disease”
and “orphan drug” preferentially in deﬁning a rare disease and the
technologies associated with rare diseases, respectively.
Relatively few deﬁnitions (o30%) included qualiﬁers relating
to disease severity and/or a lack of existing treatments, whereas
many deﬁnitions (58%) included a prevalence threshold. The
average prevalence thresholds used to deﬁne rare diseases
ranged among different jurisdictions from 5 to 76 cases/100,000
people, with a global average prevalence threshold of 40 cases/
100,000 people. Few deﬁnitions also included qualiﬁers relating to
disease severity and the lack of existing treatments.
Our results highlight the need for further research to better
understand both the extent and roots of the existing diversity of
deﬁnitions for rare diseases and to examine the scope for the
possible harmonization of the deﬁnition of rare disease within
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 9 0 6 – 9 1 4914individual jurisdictions and perhaps globally by focusing on stand-
ardizing objective criteria such as prevalence thresholds and
avoiding less rigorous qualitative descriptors. Based on our results,
the terminology “rare disease,” coupled with a prevalence thresh-
old in the range of 40 to 50 cases/100,000, could present a realistic
starting point for a harmonized deﬁnition of rare diseases.Acknowledgments
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